A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

NCT ID: NCT00269828

Last Updated: 2020-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

See Summary

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NSCLC

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Non-small cell lung cancer NSCLC PS 2 female chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

paclitaxel

Intervention Type DRUG

paclitaxel poliglumex

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female.
2. Histologically- or cytologically-confirmed diagnosis of NSCLC.
3. ECOG performance score of 2.
4. Patients who meet one of the following criteria:

* Stage IIIB who are not candidates for combined modality therapy (primary radiation therapy or surgery), or
* Stage IV.
5. Age greater than or equal to 18 years.
6. Adequate bone marrow function
7. Adequate renal function
8. Adequate hepatic function
9. Patients with known brain metastases must have received standard antitumor treatment for their CNS metastases as defined by the site's institutional standards.
10. Patients who have had major surgery must be fully recovered from the surgery.
11. Ability to comply with the visit schedule and assessments required by the protocol.
12. For patients of reproductive potential, commitment to use adequate contraception.
13. Signed approved informed consent, with understanding of study procedures.
14. Agreement to begin study therapy within 8 calendar days after randomization.

7. Clinically significant active infection for which active therapy is underway.
8. Investigational therapy within 4 weeks before randomization, unless local requirements are more stringent.
9. Unstable medical conditions including unstable angina or myocardial infarction within the past 6 months before randomization. Patients with evidence of cardiac conduction abnormalities are eligible if their cardiac status is stable.
10. Pregnant women or nursing mothers.
11. Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up.

Exclusion Criteria

1. Any intolerance to poly-L-glutamic acid, Poloxamer 188, dibasic sodium phosphate, monobasic sodium phosphate (the excipients of CT-2103).
2. Evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell histology.
3. Any prior systemic chemotherapy for the treatment of lung cancer. This includes systemic radiosensitizers used to treat brain metastases and any biologic agent.
4. Concurrent primary malignancies except for carcinoma in situ or non-melanoma skin cancer.
5. Grade 2 or greater neuropathy.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CTI BioPharma

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Desert Oasis Cancer Center

Casa Grande, Arizona, United States

Site Status

Arizona Hematology Oncology

Tucson, Arizona, United States

Site Status

Genesis Cancer Center

Hot Springs, Arkansas, United States

Site Status

Heritage Physician Group, Oncology

Hot Springs, Arkansas, United States

Site Status

Pacific Cancer Medical Center, Inc

Anaheim, California, United States

Site Status

Comprehensive Blood and Cancer Center

Bakersfield, California, United States

Site Status

Tower Cancer Research Foundation

Beverly Hills, California, United States

Site Status

Providence St. Joseph Medical Center

Burbank, California, United States

Site Status

Hematology/Oncology Group of Fresno, Inc

Fresno, California, United States

Site Status

Comprehensive Cancer Center-Research Office

Glendale, California, United States

Site Status

Loma Linda University Cancer Institute

Loma Linda, California, United States

Site Status

Pacific Shores Medical Group

Long Beach, California, United States

Site Status

Medical Oncology Care Associates

Orange, California, United States

Site Status

The Cancer Research and Prevention Center

Soquel, California, United States

Site Status

Bethesda Research Center

Boynton Beach, Florida, United States

Site Status

Broward Oncology Associates

Fort Lauderdale, Florida, United States

Site Status

Florida Wellcare

Inverness, Florida, United States

Site Status

Cancer & Blood Disease Center

Lecanto, Florida, United States

Site Status

Oncology-Hematology Associates of West Broward

Tamarac, Florida, United States

Site Status

Hematology Oncology Speaclist

Tampa, Florida, United States

Site Status

Joliet Oncology Hematology Associates, Ltd.

Joliet, Illinois, United States

Site Status

Loyola University Health Systems

Maywood, Illinois, United States

Site Status

Mid-Illinois HEM & ONC Assoc.

Normal, Illinois, United States

Site Status

Northern Indiana Cancer Research Consortium

South Bend, Indiana, United States

Site Status

Associated Physicians & Surgeons Clinic

Terre Haute, Indiana, United States

Site Status

Kentucky Cancer Clinic

Hazard, Kentucky, United States

Site Status

West Kentucky Hematology & Oncology Group, PSC

Paducah, Kentucky, United States

Site Status

Cabrini Center for Cancer Care

Alexandria, Louisiana, United States

Site Status

West Michigan Cancer Center

Kalamazoo, Michigan, United States

Site Status

Oncology Care Associates, PLLC

Saint Joseph, Michigan, United States

Site Status

Troy, Michigan, United States

Site Status

Hubert H. Humphrey Cancer Center

Robbinsdale, Minnesota, United States

Site Status

St. Louis Cancer Care Center

Chesterfield, Missouri, United States

Site Status

Columbia Comprehensive Cancer Care Clinics

Columbia, Missouri, United States

Site Status

Bond Clinic

Rolla, Missouri, United States

Site Status

Saint Louis University

St Louis, Missouri, United States

Site Status

Washington University Siteman Cancer Center Pharmacy

St Louis, Missouri, United States

Site Status

Montana Cancer Specialists

Missoula, Montana, United States

Site Status

Sierra Nevada Oncology Care

Carson City, Nevada, United States

Site Status

Essex Oncology of North Jersey, PA

Belleville, New Jersey, United States

Site Status

Atlanta HEM ONC

Manasquan, New Jersey, United States

Site Status

Oncology and Hematology Specialist, PA

Mountain Lakes, New Jersey, United States

Site Status

San Juan Oncology Association

Farmington, New Mexico, United States

Site Status

Suny Downstate Medical Center

Brooklyn, New York, United States

Site Status

Cancer Treatment Services

Corning, New York, United States

Site Status

Interlakes Foundation, Inc.

Rochester, New York, United States

Site Status

Guthrie Clinic

Sayre, New York, United States

Site Status

Our Lady of Mercy Medical Center

The Bronx, New York, United States

Site Status

New York Medical Collegw

Valhalla, New York, United States

Site Status

Alamance Cancer Center

Burlington, North Carolina, United States

Site Status

UNC Chapel Hill Oncology Protocol Office

Chapel Hill, North Carolina, United States

Site Status

Leo Jenkins Cancer Center

Greenville, North Carolina, United States

Site Status

Northwestern Carolina Oncology & Hematology

Hickory, North Carolina, United States

Site Status

St. Alexius Medical Center

Bismarck, North Dakota, United States

Site Status

University of Cleveland

Cleveland, Ohio, United States

Site Status

Metro Health Medical Center

Cleveland, Ohio, United States

Site Status

The Cleveland Clinic Foundation, Taussig Cancer Center

Cleveland, Ohio, United States

Site Status

Dayton Clinical Oncology Program

Dayton, Ohio, United States

Site Status

Signal Point Hematology/Oncology, Inc.

Middletown, Ohio, United States

Site Status

Charleston Hematology Oncology

Charleston, South Carolina, United States

Site Status

The Family Cancer Center

Collierville, Tennessee, United States

Site Status

Mary Crowley Medical Research Center

Dallas, Texas, United States

Site Status

JPS Center for Cancer Care

Fort Worth, Texas, United States

Site Status

Columbia Basin HEM/ONC

Kennewick, Washington, United States

Site Status

Sanatorio Parque

Rosario, Santa Fe Province, Argentina

Site Status

CETEN

Beunos Aires, , Argentina

Site Status

Hospital Privado de Comunidad

Buenos Aires, , Argentina

Site Status

Hospital General de Agudos "Dr Teodoro Alvarez"

Buenos Aires, , Argentina

Site Status

Instituto Alexander Fleming

Ciudad de Buenos Aires, , Argentina

Site Status

Instituto Oncologico de Cordoba - IONC

Córdoba, , Argentina

Site Status

LUCEN

Cuidad Autonoma de Buenos Aires, , Argentina

Site Status

ISIS Clinica Especializada

Urquiza, , Argentina

Site Status

District Oncology Dispensary

Plovdiv, , Bulgaria

Site Status

District Oncolodispensary with Impatient sector

Rousse, , Bulgaria

Site Status

Military Medical Academy

Sofia, , Bulgaria

Site Status

Regional Oncology Dispensary with Inpatient Secot-Sofia District

Sogia, , Bulgaria

Site Status

Regional Oncology Dispensary with Inpatient Sector

Varna, , Bulgaria

Site Status

University Mulitprofile Hospital for Active Treatment "Sveta Marina"

Varna, , Bulgaria

Site Status

University Multiprofile Hospital for Active Treatment "Sveta Marina"

Varna, , Bulgaria

Site Status

Regional Oncology Dispensary with Inpatient sector

Veliko Tarnovo, , Bulgaria

Site Status

Jewish General Hospital

Montreal, Quebec, Canada

Site Status

Erzsebet Juhasz

Budapest, , Hungary

Site Status

University of Debrecen, Pulmonology Clinic

Debreen, , Hungary

Site Status

Hospital for Thoracic Diseases of Csongrad Country

Deszk, , Hungary

Site Status

Pulmonology Institute of Veszprem County

Farkasgyepű, , Hungary

Site Status

Hospital for Pulmonological Diseases of the Bekes County

Gyula, , Hungary

Site Status

Hospital of the Chest Desease of the Hungarian Reformed Church

Mosdós, , Hungary

Site Status

Karolina Hospital

Mosonmagyaróvár, , Hungary

Site Status

Barany County Hospital

Pécs, , Hungary

Site Status

Erzsebet Hospital

Sopron, , Hungary

Site Status

Sanatorium for Pulmonological Diseases

Törökbálint, , Hungary

Site Status

Centenario Hospital Miguel Hidalgo

Aguascalientes, Aguascalientes, Mexico

Site Status

CIMA Chihuahua

Chihuahua City, Chih, Mexico

Site Status

Hospital General

Durango, Durango, Mexico

Site Status

Instituto Estatal de Cancerologia "Dr. Arturo Beltran Ortega"

Acapulco de Juárez, Guerrero, Mexico

Site Status

Hospital Dr. Angel Leano

Zapopan, Jalisco, Mexico

Site Status

Hospital Star Medica Morelina

Morelia, Michoacán, Mexico

Site Status

Monterrey International Research Center

Monterrey, N.L., Mexico

Site Status

Centro Estatal de Canceologia

Jalapa, Veracruz, Mexico

Site Status

Centro Anticanceroso de la Cruz Roja Mexicana de Merida

Mérida, Yucatán, Mexico

Site Status

Centro Estatal de Cancerologia

Chihuahua City, , Mexico

Site Status

Hospital Central "Dr. Ignacio Morones Prieto"

San Luis Potosí City, , Mexico

Site Status

Hospital General Regional

Veracruz, , Mexico

Site Status

Kujawsko-Pomorskie Centrum Pulmunologii

Bydgoszcz, , Poland

Site Status

Krakowski Szpital Specjelistyczny

Kawkow, , Poland

Site Status

Centrum Onkologii Ziemii Lubelskiej

Lublin, , Poland

Site Status

Zaklad Opieki Zdrowotnej Ministerstaw Spraw Wewnetrznych i Administraeji

Olsztyn, , Poland

Site Status

Mazowleckie Centrum leczenia Chorob Pluc i Gruzlicy

Otwock, , Poland

Site Status

Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Samodzielmy Publiczny ZOZ

Poznan, , Poland

Site Status

SPSK nr l im. Przemienienia AM w Poznaniu

Poznan, , Poland

Site Status

MSc Grezegorz Jedrejezak

Wroclaw, , Poland

Site Status

Dolnoslaskie Centrum Chorob Pluc ul. Grabiszynska 105

Wroclaw, , Poland

Site Status

Institutul Oncologie - Clinic de Oncologie Medicala

Bucharest, , Romania

Site Status

Prof. Dr. Al. Trestioreanu Institute of Oncology

Bucharest, , Romania

Site Status

"Prof. Dr. I. Chiricuta" Institute of Oncology

Cluj-Napoca, , Romania

Site Status

Emergency Clinical County Hospital

Craiova, , Romania

Site Status

Oradea Clinical County Hospital

Oradea, , Romania

Site Status

Clinical County Hospital

Sibiu, , Romania

Site Status

Timisoara Emergency Clinical Municipal Hospital

Timișoara, , Romania

Site Status

Chelyabinsk Regional Oncology Center

Chelyabinsk, , Russia

Site Status

Krasnodar City Oncology Center

Krasnodar, , Russia

Site Status

Moscow Oncology Clinical Dispensary #1

Moscow, , Russia

Site Status

SI Russian Oncological Scientific Center after N.N. Blokhim RAMS

Moscow, , Russia

Site Status

SI Russian Oncological Scientific Center after N.N. Blokhin RAMS

Moscow, , Russia

Site Status

Centeral ClinicalHospital of the President o the Russian Federation

Moscow, , Russia

Site Status

Moscow Municpal Oncology Hospital #62

Moscow Region, , Russia

Site Status

Omsk Regional Oncology Center

Omsk, , Russia

Site Status

Orenburg Regional Oncology Clinical Center

Orenburg, , Russia

Site Status

Lenigrad Regional Oncology Center

Saint Petersburg, , Russia

Site Status

Leningrad Regional Clinical Hospital

Saint Petersburg, , Russia

Site Status

St. Petersbrug State Medical Pavlov University

Saint Petersburg, , Russia

Site Status

St. Petersburg City Clinical Oncology Center

Saint Petersburg, , Russia

Site Status

Donetsk Regional Antineoplastic Center

Donetsk, , Ukraine

Site Status

Ivano-Frankovsk Regional Oncology Center, Ivano-Frankovsk Medical University

Ivano-Frankivsk, , Ukraine

Site Status

Instiute of Oncology under AMS of Ukraine

Kiev, , Ukraine

Site Status

Volyn Regional Oncology Dispensary

Lutsk, , Ukraine

Site Status

Uzhgorod National University, Regional Clinical Oncology Dispensary

Uzhhorod, , Ukraine

Site Status

Vinnitsa State Medical University

Vynnytsya, , Ukraine

Site Status

Zaporizhzhya Regional Oncology Dispensary

Zaprizhzhya, , Ukraine

Site Status

The Royal Bournemouth Hospital

Bournemouth, , United Kingdom

Site Status

Oncology Pharmacy

London, , United Kingdom

Site Status

Wythenshaw Hospital, Pharmacy Department

Manchester, , United Kingdom

Site Status

Southhampton General Hospital

Southhampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Bulgaria Canada Hungary Mexico Poland Romania Russia Ukraine United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PGT305

Identifier Type: -

Identifier Source: org_study_id

NCT00317824

Identifier Type: -

Identifier Source: nct_alias